Alcohol and other drug treatment experiences of hepatitis C-positive and negative clients: implications for hepatitis C treatment

被引:10
作者
Brener, Loren [1 ]
Treloar, Carla J. [1 ]
机构
[1] Univ New S Wales, Natl Ctr HIV Social Res, Sydney, NSW 2052, Australia
基金
英国医学研究理事会;
关键词
HEROIN USERS; DISCRIMINATION; AUSTRALIA; ATTITUDES; PROGRAMS; VIRUS; CARE;
D O I
10.1071/AH090100
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
To assess whether HCV-positive clients perceive that alcohol and other drug (AOD) staff discriminate against them, this study compared the treatment experiences of 120 HCV-positive clients with those of 120 HCV-negative clients attending the same AOD treatment facility. Despite the overall findings of favourable attitudes of HCV-positive clients toward their health care workers, these attitudes were less positive than those of their HCV-negative counterparts. Clients with HCV also rated their interpersonal treatment by their health care workers less favourably. These findings suggest that HCV-positive clients' attitudes towards their health care workers and their experiences of differential treatment by these health care workers might be a barrier to HCV treatment uptake in AOD treatment facilities.
引用
收藏
页码:100 / 106
页数:7
相关论文
共 50 条
  • [41] Alternative interferons and immunomodulators in the treatment of hepatitis C
    Alao, Hawwa
    Liang, T. Jake
    LIVER INTERNATIONAL, 2014, 34 : 133 - 138
  • [42] Treatment of acute hepatitis C in HIV infection
    Vogel, Martin
    Rockstroh, Juergen K.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (01) : 4 - 9
  • [43] Current progress in the treatment of chronic hepatitis C
    Alexopoulou, Alexandra
    Papatheodoridis, George V.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (42) : 6060 - 6069
  • [44] New developments in the antiviral treatment of hepatitis C
    de Bruijne, J.
    Weegink, C. J.
    Jansen, P. L. M.
    Reesink, H. W.
    VOX SANGUINIS, 2009, 97 (01) : 1 - 12
  • [45] Virological monitoring of hepatitis C treatment in 2009
    Cacoub, P.
    Halfon, P.
    REVUE DE MEDECINE INTERNE, 2009, 30 (10): : 838 - 840
  • [46] Telaprevir for the treatment of chronic hepatitis C infection
    Muir, Andrew J.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (12) : 1105 - 1114
  • [47] Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
    Litzroth, Amber
    Suin, Vanessa
    Wyndham-Thomas, Chloe
    Quoilin, Sophie
    Muyldermans, Gaetan
    Vanwolleghem, Thomas
    Kabamba-Mukadi, Benoit
    Verburgh, Vera
    Jacques, Marjorie
    Van Gucht, Steven
    Hutse, Veronik
    BMC PUBLIC HEALTH, 2019, 19 (1)
  • [48] Treatment of Hepatitis C: State of the Art 2018
    Zeuzem, Stefan
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2018, 143 (24) : 1784 - 1788
  • [49] Hepatitis C Knowledge and Alcohol Consumption among Patients Receiving Methadone Maintenance Treatment in Shanghai, China
    Du, Jiang
    Wang, Zhen
    Xie, Bin
    Zhao, Min
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2012, 38 (03) : 228 - 232
  • [50] Treatment failure with new hepatitis C drugs
    Soriano, Vincent
    Vispo, Eugenia
    Poveda, Eva
    Labarga, Pablo
    Barreiro, Pablo
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (03) : 313 - 323